TNFRSF13C and adenocarcinoma: With regard to membranous BAFFR, patients with adenocarcinomas and no BAFFR expression had better three- and five-year OS compared to patients whose tumors expressed BAFFR (Figure 4a, p = 0.007 and p = 0.022, respectively).